JOHN HOPE FRANKLIN CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1838-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.duke.edu
Immunotherapy in Treating Patients With Metastatic Breast Cancer
Phase 1
Terminated
- Conditions
- Breast Cancer
- Interventions
- Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- First Posted Date
- 2003-04-25
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 4
- Registration Number
- NCT00003432
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: CEA peptide 1-6D
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Duke University
- Target Recruit Count
- 4
- Registration Number
- NCT00057915
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Coping Skills Training for Early Rheumatoid Arthritis
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Behavioral: Comprehensive Coping Skills TrainingBehavioral: Arthritis Education SessionsBehavioral: Standard Care
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 105
- Registration Number
- NCT00056394
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Weight Loss Maintenance (WLM)
Not Applicable
Completed
- Conditions
- Cardiovascular DiseasesHeart DiseasesObesityDiabetes Mellitus, Non-insulin DependentHypertension
- Interventions
- Behavioral: Personal contact (PC)Behavioral: Interactive technology (IT)
- First Posted Date
- 2003-02-14
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1685
- Registration Number
- NCT00054925
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00006474
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Phase 1
Completed
- Conditions
- NeuroblastomaBrain and Central Nervous System TumorsMetastatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Duke University
- Registration Number
- NCT00003461
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00016991
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Phase 2
Completed
- Conditions
- Brain and Central Nervous System TumorsNeuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005955
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Phase 1
Completed
- Conditions
- Brain and Central Nervous System TumorsChildhood Germ Cell TumorHead and Neck CancerKidney CancerNeuroblastomaOvarian CancerSarcomaTesticular Germ Cell Tumor
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT00005952
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide in Treating Patients With Brain Metastases
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005954
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath